Biologics License Application BLA

Related by string. Biologic License Application BLA * biologics . BioLogic . biologic : submitted Biologics License . biologic therapies . vaccines biologic therapies / licenses . Licenses : DRIVING WHILE LICENSE REVOKED . specialty license plates / Applications . applications : Application Delivery Networking . Oracle Application Server / Blad . bla : BLA submission . assigned Dyax BLA * *

Related by context. All words. (Click for frequent words.) 86 Biologics License Application 77 New Drug Application 75 supplemental Biologics License Application 75 Marketing Authorization Application 75 Marketing Authorization Application MAA 74 Biologic License Application 72 NDA submission 72 Biologic License Application BLA 72 sBLA 71 BLA submission 70 application sNDA 70 sNDA 70 Application BLA 70 Marketing Authorisation Application 69 Premarket Approval PMA 68 Complete Response 68 registrational 68 Biological License Application 68 BLA filing 67 IND Investigational New 67 Marketing Authorisation Application MAA 67 Premarket Approval Application 66 oral ridaforolimus 66 FDA Approvable Letter 65 Orathecin 65 NEBIDO 65 supplemental biologics 65 FDA Complete Response 65 sNDA filing 65 Omigard 65 Pivotal Phase III 65 APF# NDA 65 Intermezzo ® NDA 64 Files Investigational 64 FOLOTYN ® 64 JOULFERON 64 Civacir 64 NDA Submission 64 alvimopan 64 Drug Submission 64 PREOS 64 lorcaserin NDA 64 MAA submission 64 PREOS R 64 ZEGERID Capsules 64 FDA approvable letter 64 Fast Track designation 63 Biologics Licensing 63 FDA Accepts 63 PIX# trial 63 PMA submission 63 IND submission 63 T Pred 63 Exocrine Pancreatic Insufficiency 63 RANK Ligand inhibitor 63 Cellegesic 63 ruxolitinib 63 BLOOM DM 63 CIP TRAMADOL ER 63 Voraxaze 63 Marqibo 63 Market Approval PMA 62 Zenvia ™ 62 Rhucin R 62 vilazodone 62 Investigational Device Exemption 62 Fodosine 62 BENLYSTA 62 Soliris TM eculizumab 62 Prostate AdenoCarcinoma Treatment 62 IMPACT IMmunotherapy 62 testosterone gel LibiGel 62 INDs 62 PDUFA date 62 L MTP PE 62 StaphVAX R 62 Marketing Authorization Applications 62 Junovan 62 Market Authorization Application 62 Oracea TM 62 ANTEGREN 61 taliglucerase alfa 61 octreotide implant 61 Application MAA 61 Corlux 61 Accelerated Approval 61 sNDA submission 61 pivotal Phase III 61 Augment Bone Graft 61 proprietary transdermal patch 61 OFIRMEV 61 Zelrix 61 Pirfenidone 61 balsalazide tablet 61 prGCD 61 Rhucin ® 61 phase IIb clinical 61 severe hypercholesterolemia 61 NDA resubmission 61 NEBIDO R 61 RIGScan CR 61 LibiGel ® 61 VIVITROL ® 61 PROVENGE sipuleucel T 61 Exelbine 61 Dalbavancin 61 Phase IIa trial 61 KRYSTEXXA TM pegloticase 61 rolling Biologics License 60 liver resection surgeries 60 ITAX 60 ISO Vorin TM 60 virus HCV protease inhibitor 60 autologous cellular immunotherapy 60 Rhucin 60 ZEGERID Chewable Tablets 60 tiapamil 60 Augment Injectable 60 vinorelbine emulsion 60 nasal calcitonin product 60 Esbriet pirfenidone 60 SYCREST 60 HP Acthar Gel repository 60 Dacogen injection 60 GRAS notification 60 Personalized Immunotherapy 60 indiplon capsules 60 k premarket 60 Investigational 60 Investigational Device Exemption IDE 60 ENTEREG ® 60 Act PDUFA date 60 MONOVISC 60 Complete Response letter 60 hoFH 60 Acetavance 60 Phase IIIb clinical 60 NUVIGIL 60 DPX Survivac 60 DASISION 60 Nabi HB Intravenous 60 peginesatide 60 Somatuline R Autogel R 60 UPLYSO 60 IIa trial 60 BRILINTA 60 MK #B 60 PROVENGE ® 60 SUCCEED trial 60 Clinical Trial Application 60 PLK1 SNALP 60 mesylate tablets 60 Viviant 60 OvaRex ® MAb 60 Phase 2b clinical 60 Nasdaq VRTX 60 FACTIVE R gemifloxacin 60 Raptiva R 60 fidaxomicin 60 Biologics License Applications 60 RSR# 60 submit Biologics License 60 Exelbine NDA 60 Contrave NDA 59 Phenoptin 59 ponatinib 59 Anturol TM 59 ATryn R 59 Topical Interferon Alpha 2b 59 Camvia 59 CRMD# 59 BENLYSTA ® 59 Omigard TM 59 LymphoStat B TM 59 Prestara TM 59 ATPace TM 59 OLpur TM H2H 59 Phase IIb clinical trials 59 ONCONASE 59 ENRICH trial 59 KALBITOR ® 59 Premarket Approval 59 Supplemental Biologics License Application 59 Acetavance TM 59 ANDA containing 59 highly purified pasteurized 59 Phase III pivotal 59 Luveniq 59 Premarket Notification 59 Glybera R 59 PANVAC VF 59 dextromethorphan quinidine 59 SILENOR TM 59 Phase III clinical 59 BYETTA ® 59 Aurexis 59 ADVEXIN 59 JZP 59 Zenvia TM 59 Emezine 59 Levoleucovorin 59 ALN PCS 59 IND CTA 59 Icatibant 59 ZOLINZA 59 torezolid phosphate 59 ATryn ® 59 granted Ortec 59 Phase IIb clinical 59 ZALBIN 59 Release Capsules 59 Orphan Drug status 59 ULTRASE 59 HCV protease inhibitor 59 Velac 59 Neuromodulation System 59 BLP# Liposome Vaccine 59 Firazyr 59 LibiGel NDA 59 Priority Review 59 Amoxicillin PULSYS 59 dirucotide 59 Bazedoxifene 58 Telavancin 58 VALSTAR 58 dose escalation clinical 58 Ketotransdel 58 Staphylococcus aureus Polysaccharide Conjugate 58 velaglucerase alfa 58 Surfaxin LS 58 ONGLYZA ™ 58 candidate Zentase 58 trastuzumab DM1 T DM1 58 Romiplostim 58 Renvela 58 Elagolix 58 methylnaltrexone bromide 58 QNEXA 58 R sipuleucel T 58 Marketing Authorisation 58 MyVax R 58 Approvable letter 58 Evoltra ® 58 Clevudine 58 novel histone deacetylase 58 Evoltra 58 ZEVALIN ® 58 Panzem R 58 pseudobulbar affect PBA 58 Cladribine Tablets 58 Plicera 58 BLA 58 lucinactant 58 Dyloject TM 58 Targretin capsules 58 Ereska 58 investigational humanized monoclonal antibody 58 ezogabine 58 OLEPTRO 58 maribavir 58 THALOMID 58 initiate Phase IIb 58 EOquin 58 human C1 inhibitor 58 Pixuvri 58 AzaSite Plus 58 subcutaneous formulation 58 markets HP Acthar 58 Saforis 58 Ceplene 58 Marketing Authorization 58 zolpidem tartrate sublingual tablet 58 VISICOL R 58 teduglutide 58 Phase III Clinical Trial 58 SPRYCEL ® 58 Rhucin ® recombinant 58 confirmatory Phase 3 58 sNDAs 58 REPLAGAL 58 refractory chronic lymphocytic 58 AVASTIN 58 COMFORT II 58 Drug Submission NDS 58 License Application sBLA 58 Submits Supplemental 58 phase IIa 58 NADiA ProsVue 58 corticotropin injection 58 Allovectin 7 58 Orphan Drug designations 58 NASDAQ CXSP announced 58 Frova ® 58 Calcium Acetate 58 Cimzia TM 58 PMA Supplement 58 MOZOBIL 58 PDX pralatrexate 58 SUMAVEL 58 eprodisate KIACTA TM 58 CLIA waiver 58 Zenpep 58 Kynapid 58 HepaGam B 58 submitted Biologics License 58 Clolar ® 58 Matrix Phase 2b 58 tafamidis 58 DR Cysteamine 58 ROTATEQ 58 adecatumumab MT# 58 Bronchitol 58 Product Monograph 58 LEVADEX ™ 58 Soliris eculizumab 58 Stavzor 58 registrational trial 58 L BLP# 58 Ixempra 58 APF# 58 OrCel R 58 ILUVIEN ® 58 CERVARIX R 58 diarrhea predominant irritable 58 faropenem 57 Urocidin 57 generation purine nucleoside 57 Phase Ib study 57 Restanza 57 novel emulsion formulation 57 Announces Tentative Approval 57 Onalta ™ 57 pixantrone NDA 57 ONCONASE R 57 Lenocta TM 57 thymalfasin 57 TRANSDUR Sufentanil 57 Nebido 57 Kuvan TM sapropterin 57 Phase IIb Clinical Trial 57 Polymer Microspheres 57 phase IIb trial 57 SPARLON 57 albinterferon alfa 2b 57 ADVEXIN p# therapy 57 DAYTRANA TM 57 intravenous acetaminophen 57 CIP ISOTRETINOIN 57 NYSE Amex PTN 57 OMP designation 57 PDUFA Date 57 Fortigel 57 GATTEX TM 57 ridaforolimus 57 forodesine 57 XiDay 57 Veronate 57 GALNS 57 REMOXY NDA 57 Mepact 57 Phase III clinical trials 57 Vectibix panitumumab 57 Somatuline Depot 57 alogliptin 57 cutaneous T 57 Oral Calcitonin 57 alvespimycin 57 CryoSeal FS System 57 Ambrisentan 57 Advexin 57 Pivotal Phase 57 Mutual Recognition Procedure 57 Intermezzo R 57 Phase 2b study 57 Zolpimist 57 METOZOLV ODT 57 bazedoxifene 57 Rescula 57 ALN TTR 57 orphan designation 57 Zalbin 57 commercialize oritavancin 57 dalbavancin 57 OMAPRO ™ 57 Drug Eluting Stent System 57 telavancin NDA 57 IND 57 Granted Orphan Drug 57 RELISTOR ® 57 oral prodrug 57 Phase #/#a trial 57 REPEL CV 57 acyclovir Lauriad ® 57 CHMP recommendation 57 ibuprofen Injection 57 FIRMAGON R 57 Zenvia Phase III 57 vinflunine 57 metastatic hormone refractory 57 Viramidine 57 Archexin 57 Cetrorelix 57 BRIM3 57 BLAs 57 Genasense ® oblimersen 57 Jevtana 57 ANDAs 57 Nasdaq OPTR 57 Evoltra R 57 Horizant 57 XIAFLEX ™ 57 Onco TCS 57 metastatic castrate resistant 57 New Drug IND 57 confirmatory Phase III 57 Zingo TM 57 Pruvel 57 Sular formulation 57 StaphVAX 57 Relistor 57 Tezampanel 57 Oporia 57 IND Application 57 Linjeta TM 57 Fortical R 57 investigational 57 PNP inhibitor 57 HDAC Inhibitor 57 metastatic sarcomas 57 Cinryze TM 57 CORTOSS Bone Augmentation Material 57 Phase 2b trial 57 Ceplene TM 57 investigational pan BCR 57 Cloretazine ® 57 HepeX B TM 57 PROGENSA R 57 SILENOR 57 Phase Ib 57 FOLOTYN 57 Keppra ® XR 57 Trizytek 57 Iluvien ® 57 PDE4 inhibitor 57 histamine dihydrochloride 57 Sanctura XR 57 Drug Application 57 Phase lll 57 Oracea 57 ongoing Phase 1b 57 Telatinib 57 oral methylnaltrexone 57 LUVENIQ 57 Junovan TM 57 Phase 1b dose escalation 57 ZEGERID Powder 57 Complete Response Letter 57 Velaglucerase Alfa 57 SNT MC# 57 Ustekinumab 57 ecallantide 57 OMAPRO 57 Submits Investigational 57 Completes Patient Enrollment 57 Bonefos 57 acyclovir Lauriad R 57 Initiate Phase 57 ACUROX 57 Fast Track Status 57 Fast Track designations 57 Arzerra TM 57 Aryplase 56 k Premarket Notification 56 EFAPROXYN 56 pralatrexate 56 FUSILEV ® 56 zileuton CR 56 Zensana 56 Hematide ™ peginesatide 56 TYGACIL 56 Orphan Drug Designation 56 Plenaxis TM 56 Phase IIb trials 56 Stimuvax R 56 Evoltra TM 56 topically applied SEPA 56 POSIDUR TM 56 Silenor NDA 56 Loramyc 56 ofatumumab HuMax CD# 56 Pralatrexate 56 GTC recombinant human 56 Expedited Review 56 Brentuximab Vedotin SGN 56 OraTest 56 ALVESCO R 56 FavId 56 IV acetaminophen 56 Phase IIIb 56 Virulizin R 56 granulated mesalamine 56 oral calcitonin 56 Preotact 56 Phase IIB 56 ORENCIA R 56 SPL# Gel vaginal microbicide 56 Patient Enrollment 56 Extina 56 AP# [003] 56 Arzerra ofatumumab 56 oral nucleoside analogue 56 phase IIa clinical 56 Neurodex TM 56 MAXY alpha 56 INCB# [002] 56 MAGE A3 ASCI 56 rasagiline tablets 56 elotuzumab 56 Phase Ib II 56 IL# PE#QQR 56 Kuvan R 56 Xibrom QD 56 BEMA Fentanyl 56 NPSP# 56 Mycograb 56 LUCASSIN 56 Aloxi Injection 56 TAXUS Element Stent System 56 OLEPTRO TM 56 investigational hepatitis B 56 Mylan Receives Approval 56 candidate REP# 56 Augment ™ 56 lymphoma CTCL 56 lexidronam injection 56 Approvable Letter 56 Q#IR 56 Orphan Drug designation 56 Pivotal Trial 56 ixabepilone 56 novel bactericidal 56 Ruconest 56 CLIRS trial 56 TELINTRA 56 clofarabine 56 Clolar 56 nanofiltered plasma derived 56 Silenor ® 56 pralatrexate injection 56 Phase IIa trials 56 Drug Applications ANDAs 56 novel oral anticoagulant 56 bicifadine 56 cystinosis patients 56 liprotamase 56 Firazyr ® 56 commercialize toremifene 56 SPD# 56 Troxatyl 56 ofatumumab 56 Initiates Phase II 56 PrevOnco 56 submitted supplemental Biologics 56 BYDUREON 56 Pennsaid 56 PrevOnco ™ 56 Sprycel dasatinib 56 Dextofisopam 56 HuMax CD4 56 Anidulafungin 56 resubmission 56 Vilazodone 56 interferon gamma 1b 56 Fibrillex TM 56 Vion Pharmaceuticals 56 ambrisentan 56 Neurodex 56 Azedra 56 non nucleoside inhibitor 56 Prodarsan R 56 PI3K/Akt pathway inhibitor 56 Phase III Pivotal 56 Trelstar R 56 ZADAXIN ® 56 non constipation irritable 56 assessing T DM1 56 Ofirmev 56 GTC recombinant form 56 refractory APL 56 Phase 2b 56 Glybera 56 oxymorphone ER 56 apaziquone 56 Phase 2a clinical trials 56 Impax ANDA 56 OvaRex R 56 Onrigin 56 Raptiva ® 56 M Enoxaparin 56 Kit CD# positive 56 Phase IIb 56 histone deacetylase HDAC inhibitor 56 Nexavar sorafenib 56 Xolegel 56 fidaxomicin Phase 56 NASDAQ INGN 56 LIALDA 56 treat male hypogonadism 56 Octreolin 55 FDA Investigational Device 55 phase IIb 55 Bioral ® 55 Trofex 55 miconazole Lauriad R 55 PRNewswire FirstCall Genta Incorporated 55 SUTENT ® 55 rALLy clinical trial 55 Phase #b/#a clinical 55 Phase III TRIST 55 Alvesco R 55 FDA Orphan Drug 55 LidoPAIN SP 55 Submits NDA 55 sitaxsentan sodium 55 Fast Track Designation 55 FIRAZYR 55 pivotal Phase 55 Fx #A 55 Initiate Clinical Trial 55 cell lymphoma CTCL 55 eniluracil 55 Pafuramidine 55 CEQ# 55 CIMZIA r 55 DIFICID ™ 55 Argatroban 55 Opterone R 55 desvenlafaxine 55 Phase 1b trial 55 Release Tablets 55 Phase 2a clinical 55 OPAXIO 55 Initiates Enrollment 55 Manja Bouman CEO 55 Ranexa R 55 cutaneous T cell 55 omacetaxine mepesuccinate 55 Omapro 55 sumatriptan injection 55 Inhalation Solution 55 overactive bladder AA# 55 Panzem R NCD 55 Pennsaid R 55 brentuximab 55 Phase III Clinical Trials 55 MOVIPREP R 55 KRYSTEXXA TM 55 Ceflatonin 55 European Medicines Evaluation 55 Orphan Drug Status 55 Metformin GR 55 initiate Phase 1b 55 OrCel ® 55 refractory Hodgkin lymphoma 55 R bendamustine hydrochloride 55 Actemra tocilizumab 55 Feraheme ® 55 Zerenex 55 rNAPc2 55 PRECISE trial 55 RIGScan ™ 55 Paragraph IV 55 Inc. Nasdaq CYCC 55 Pivotal Clinical Trial 55 SWX BSLN 55 sodium Injection 55 Loramyc R 55 TOCOSOL Paclitaxel 55 Exalgo 55 approvable letters 55 Celgene Thalomid 55 Phase 2a trial 55 sapropterin dihydrochloride 55 NUEDEXTA ™ 55 Xcytrin R 55 JAK inhibitor 55 Allovectin 7 r 55 SmPC 55 TREANDA 55 Phase III 55 cervical cancer vaccine Cervarix 55 formerly LymphoStat B 55 Oracea R 55 IMA# 55 Marketing Approval PMA 55 crizotinib PF # 55 Evamist TM 55 Orapred ODT 55 Preotact R 55 SUPPRELIN R LA 55 PhosLo 55 LEUKINE 55 azficel T 55 Cleviprex TM clevidipine 55 ABL inhibitor 55 FDA Oncologic Drugs 55 octreotide acetate 55 Hematide ™ 55 Fentanyl TAIFUN R 55 systemic anaplastic large 55 Fidaxomicin 55 Product Characteristics 55 ferumoxytol Injection 55 investigational therapies 55 PEG SN# 55 Provenge prostate cancer 55 investigational hepatitis C 55 Cinryze ™ 55 Resubmission 55 HCl capsules 55 eprodisate Fibrillex TM 55 linaclotide 55 candidate XP# 55 ® decitabine 55 Roflumilast 55 IV APAP 55 CONBRIZA 55 SEBIVO 55 valopicitabine 55 amifampridine phosphate 55 humanized anti 55 omacetaxine 55 Hedgehog antagonist 55 Mozobil 55 Japanese Encephalitis vaccine 55 nonclinical studies 55 VALSTAR R 55 Soriatane 55 XL# anticancer compounds 55 Tarceva TM 55 sapacitabine 55 Trobalt 55 Velcade bortezomib 55 tezampanel 55 VEGF Trap 55 AAG geldanamycin analog 55 CORTOSS 55 HoFH 55 Zensana TM 55 Pegloticase 55 Silenor ® doxepin 55 COLAZAL R 55 Entereg R 55 5 HT3 antagonist 55 rhThrombin 55 relapsed refractory multiple myeloma 55 rThrombin 55 OMNARIS HFA 55 TransVax TM 55 IND Filing 55 Ventavis 55 Amoxicillin PULSYS Phase III 55 Dupuytren Contracture 55 JZP 6 55 lintuzumab SGN 55 ATD TM gel 55 Traficet EN 55 PROMACTA ® 55 Phase IIb Trial 55 Surfaxin lucinactant 55 Proxinium TM 55 CCR5 antagonist 55 investigational antiplatelet agent 55 GRALISE 55 Moxatag 55 Combidex 55 BRIM2 55 Efficacy Results 55 Phase IIb III 55 antibody MAb 55 cancer neuroendocrine tumor 55 IONSYS TM 55 methylnaltrexone 55 satraplatin 55 PRECISE Trial 55 tramiprosate ALZHEMED TM 55 Clofarabine 55 REBETOL combination therapy 55 Spiegelmer ® 55 Fibrin Pad 55 NGX# 55 BEMA TM Fentanyl 55 Centralized Procedure 55 GENERIC SILDENAFIL SOFT Generic 55 naproxen esomeprazole magnesium 55 mitogen activated ERK kinase 55 Antegren 55 Board DSMB 55 investigational oral hepatitis C 55 Nasdaq PGNX today 55 Generx ™ 55 GARDASIL ® 55 Phase 1a clinical 55 Sutent sunitinib 55 Joulferon 55 CDP# 55 Xyrem ® 55 Nasdaq DVAX 55 tolevamer 55 OncoVEX GM CSF 55 STELARA TM 55 vidofludimus 55 REMOXY R 55 % uracil topical 55 Allovectin 7 R 55 Intermezzo ® 55 Ganite R 55 anticancer compound 55 IMC #B 54 Phase IIa clinical 54 balsalazide disodium 54 Phase 2b Clinical Trial 54 Liberte TM 54 arzoxifene 54 LEVADEX TM 54 CUSTOM III 54 CoFactor 54 Inhalation Aerosol 54 Loramyc ® 54 cinacalcet HCl 54 S OMX GEN 54 Ganite ® 54 LHRH antagonist 54 budesonide MMX 54 Oracea ® 54 Receives Orphan Drug 54 TSX SHQ 54 RECOTHROM R 54 miconazole MBT 54 Alzhemed TM 54 Nasdaq HALO 54 ospemifene 54 Riquent 54 Ferumoxytol 54 Increlex TM 54 NM# [001] 54 PULSYS 54 Master File DMF 54 Gestiva TM 54 ORENCIA ® 54 Reloxin ® 54 Xgeva 54 Inc. OTCBB VODG 54 Nexavar ® 54 GAMMAGARD 54 Phase 1b 54 Durezol TM 54 MyVax 54 orphan medicinal product 54 Somatuline Autogel 54 AMD# [002] 54 Esbriet ® 54 INSPIRE Trial Phase III 54 Abstral 54 Pivotal Study 54 Tasigna nilotinib 54 Phase #b/#a 54 Act PDUFA 54 orBec 54 Zorbtive TM 54 Phase III randomized controlled 54 Presents Positive 54 SEASONIQUE TM 54 Perflubutane Polymer Microspheres 54 SinuNase TM 54 Treanda 54 MEND CABG II 54 CORLUX 54 ONSOLIS 54 Special Protocol Assessment 54 GATTEX ® 54 OvaDx 54 brivaracetam 54 PROSTASCINT R 54 Anturol ® 54 Onsolis 54 DOS# 54 AVADO 54 ASONEP TM 54 Barr ANDA 54 Drug Applications NDAs 54 talactoferrin 54 SinuNase ™ 54 Submits Biologics License Application 54 Firdapse 54 Besivance 54 clevudine 54 sorafenib tablets 54 phase III isavuconazole 54 Flutiform ™ 54 HepeX B 54 Cimzia ® 54 Thelin TM 54 immunotherapeutic agent 54 CINTREDEKIN BESUDOTOX 54 DAVANAT R 54 Phase IIB clinical 54 sterile lidocaine patch 54 Tarsa Therapeutics 54 Ketotransdel ® 54 ANDA Abbreviated New 54 multicenter Phase 54 vosaroxin 54 PLAVIX ® 54 Inc. Nasdaq VVUS 54 risedronate sodium 54 Nivestim 54 OROS R Hydromorphone 54 NOXAFIL 54 human lactoferrin 54 AMITIZA R 54 Rebif ® 54 Lenocta 54 Apricus Bio 54 lomitapide 54 INCB# [001] 54 generation NNRTI 54 ketolide antibiotic 54 ARIKACE 54 Cimzia ® certolizumab pegol 54 Genasense ® 54 CLARITY study 54 Itopride 54 pantoprazole sodium 54 product BioThrax ® 54 Phase 2a Trial 54 Certican 54 Crofelemer budesonide foam 54 DPP4 54 phase 2a 54 diabetic neuropathic pain 54 MoxDuo IR 54 sublingual tablets 54 ELACYT 54 ThermoDox ® 54 Plenaxis R 54 phase IIb study 54 PF # [002] 54 molecular imaging radiopharmaceutical 54 Receives Orphan Drug Designation 54 ISENTRESS raltegravir 54 candidates bavituximab 54 Ceftobiprole 54 oxybutynin ATD TM 54 Lucanix R 54 Solzira 54 Torisel 54 cetuximab Erbitux R 54 sumatriptan DosePro 54 Proellex TM 54 Alferon N Injection 54 By JAMAAL ABDUL 54 R vancomycin hydrochloride 54 Insegia 54 Nuvion 54 randomized controlled Phase 54 SAFLUTAN 54 GLP1 agonist 54 ELADUR ™ 54 mesylate tablets approved 54 evaluating satraplatin 54 rALLy trial 54 sevelamer carbonate 54 catheter occlusion 54 Inc. Amex SYI 54 Receives Approvable Letter 54 MKC# MT 54 ZEFTERA ™ 54 initiate Phase Ib 54 inhaled liposomal ciprofloxacin 54 Initiated Phase 54 motexafin gadolinium Injection 54 Vitrasert R 54 ocular formulation 54 PROVIGIL 54 Drug Administration FDA Oncologic 54 IMPACT DCM 54 XGEVA ™ 54 Gencaro 54 including eniluracil ADH 54 ATryn ® GTC recombinant 54 HGS ETR2 54 miconazole Lauriad 54 aclidinium bromide 54 NasdaqGM NTEC today 54 Submits IND 54 Hedgehog Pathway Inhibitor 54 CHMP opinion 54 POSIDUR TM ELADUR TM

Back to home page